
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching around $18 billion in 2020, which underscores a robust demand for ADHD treatment solutions. The company's proprietary precision timed-release drug delivery platform has shown promise, demonstrated by the positive topline results from the CTx-1301 trial in July 2023, indicating enhanced efficacy compared to placebo. These elements combine to present a favorable outlook for Cingulate's stock, as the company is well-positioned to capitalize on the evolving treatment landscape amidst significant market opportunities.
Bears say
Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which fell short of both internal estimates and consensus expectations. Additionally, the company recorded a larger net loss of $7.3 million in a previous period, with an EPS of $(1.35), indicating continued financial strain and operational challenges. Key risks impacting the company's outlook include balance sheet stability, the potential failure of product candidates in clinical trials, regulatory approval hurdles, commercialization difficulties, and broader market factors affecting investor sentiment in the biotech sector.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares